SARS-CoV-2 Delta Variant Predominant at a Tertiary-Care Hospital in Saudi Arabia

Alhamlan, Fatimah S.; Al‐Qahtani, Ahmed; Obeid, Dalia; Al-Jumaah, Suliman; Al‐Ghamdi, Sami G.; Alnafee, Khaled; Alsanea, Madain; Alahideb, Basma; Almutairi, Shuruq; Alsuwairi, Feda; Al-Abdulkarim, Maha; Asiri, Mohamed; Alkahtani, Jalwa; Altamimi, Sara; Mutabagani, Maysoon S.; Althawadi, Sahar; Almaghrabi, Reem S.

doi:10.21203/rs.3.rs-779549/v1

Cited by 8 publications

(13 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the HCWs agreed that the Delta variant could cause a new COVID-19 wave within Saudi Arabia, although the reported cases were still limited at the time of our study [7]. This could represent the knowledge of the HCWs of the rapidly evolution of the Delta variant globally, as the COVID-19 virus is becoming 'fitter and faster' [40].…”

Section: Discussionmentioning

confidence: 87%

“…However, there has been growing concern about the level of protection that approved vaccines can provide, as well as the evasion mechanisms. In early May 2021, of 321 patients hospitalized with COVID-19 at a tertiary care center in Riyadh, 131 had the Delta variant [7]. A recent study from Qatar, a neighboring country to KSA, showed an accelerating decline in the effectiveness of BNT162b2 against all variants to 20% five to seven months after the second dose [39].…”

Section: Discussionmentioning

confidence: 99%

“…In Delhi, the Delta variant accounted for 60% of all sequenced samples [5,6]. In Saudi Arabia, a recent pre-publication study of 320 SARS-CoV-2 sequenced samples showed that 40.9% to be Delta variant, 15.9% Beta, and 11.6% alpha variant [7]. Neutralizing antibodies collected 12 months after infection from convalescent sera were fourfold less potent against the Delta variant compared to the Alpha variant [8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers

et al. 2021

View full text Add to dashboard Cite

Background: As the COVID-19 Delta variant has spread across the globe, healthcare workers’ (HCWs) knowledge, worries, and vaccine booster acceptance should be assessed. Methods: Online questionnaires aimed at HCWs in Saudi Arabia were distributed between 9 and 12 August 2021, aiming to evaluate HCWs’ perceptions and worries about the Delta variant as well as their feelings about receiving a booster-vaccine. Results: A total of 1279 HCWs participated, with 51.1% being physicians and 41.7% nurses. 92.5% were aware of the emergence of the Delta variant. Still, only 28.7% were found to have sufficient knowledge of the variant, and their level of worry about it was higher than their level of worry about the Alpha variant (2.32/5 versus 1.79/5). The main information sources cited by the participants were social media (50.5%), while 30.5% used scientific journals. Overall, 55.3% were willing to receive a vaccine booster, while one third would have preferred to receive a new mRNA vaccine specifically developed for the Delta variant. Factors associated with vaccine booster acceptance were receiving both vaccination doses (p = 0.008), believing that the Pfizer-BioNTech BNT162b2 vaccine is effective against variants (p < 0.001), and agreement that mixing/matching vaccines is effective against variants (p < 0.001). Conclusions: A high percentage of HCWs were aware of the Delta variant, but only a small fraction had decent quality of knowledge about it. The participants exhibited high worry levels and showed a modest acceptance of receiving a vaccine booster dose. These results should encourage public health officials to scale up educational efforts to disseminate reliable information about the different variants and provide recommendations about receiving a vaccine booster. Further research on methods to alleviate HCWs’ worries about emerging variants is warranted.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In our cohort, all patients with OI had mild COVID-19, did not require hospitalization, and recovered without complications. Almost half of the patients develop COVID-19 before vaccination or after partial vaccination during the period of circulating SARS-CoV-2 variants of concern, predominately SARS-CoV-2 Delta virus ( 14 ). Nine out of 12 patients were less than 18 years old, 41% were chair bound, and 41% had kyphoscoliosis.…”

Section: Discussionmentioning

confidence: 99%

Outcome of COVID19 in Patients With Osteogenesis Imperfecta: A Retrospective Multicenter Study in Saudi Arabia

et al. 2022

View full text Add to dashboard Cite

BackgroundAlthough genetic diseases are rare, children with such conditions who get infected with COVID-19 tend to have a severe illness requiring hospitalization. Osteogenesis imperfecta (OI) is a rare genetic disorder of collagen resulting in fractures and skeletal deformities. Kyphoscoliosis, restrictive lung disease, and pneumonia worsen the prognosis of patients with OI. The use of bisphosphonate improves bone mineral density (BMD) and reduces fractures in OI. There is no literature describing the impact of COVID-19 in patients with OI.MethodologyA retrospective multi-center study was performed in three hospitals in Jeddah and Riyadh, Saudi Arabia, from March 1st, 2020, until August 31st, 2021, aiming to evaluate the outcome of COVID-19 in patients with OI. Demographics, vaccination status, underlying kyphoscoliosis, functional status, use of bisphosphonate, BMD, and COVID-19 severity, and course were recorded for all patients.ResultsTwelve cases of confirmed COVID-19 were identified among 146 patients with OI. 9 (75%) of patients were less than 18 years, 6 (50%) were male, 5 (41%) had kyphoscoliosis, and 5 (41%) were wheelchair-bound. 6 (50%) received bisphosphonate, and 7(58%) had normal BMD. All patients had mild disease and did not require hospitalization. None of OI the patients with COVID-19 were fully vaccinated before the infection, and some were ineligible for vaccination.ConclusionPatients with OI and COVID-19 in our study recovered without complications, unlike patients with other genetic diseases. Young age and mild illness contributed to the favorable outcome. Half of the patients received bisphosphonate and had normal BMD.

show abstract

“…Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, different variants of the causative virus-the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-have been discovered globally, including the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. The medical community must further understand their transmission and diagnosis to detect them early and reduce infection by applying the best preventive measures [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Types of Variants Among Increased Cases of COVID-19 in the Western Region of Saudi Arabia in June 2021

Alahmad¹,

Kamel²,

Alsulimani³

et al. 2022

Cureus

View full text Add to dashboard Cite

Background The western region of Saudi Arabia is the most populous and diverse. This study aimed to identify the types and distribution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants causing cases of coronavirus disease 2019 (COVID-19) in this region in June 2021. Methods We conducted a cross-sectional study. All genetically tested COVID-19 patients were included. We investigated the types, distribution, and magnitude of SARS-CoV-2 variants among cases of COVID-19 in June 2021. We gathered patient demographic data, clinical profiles, and epidemiology data. Results Of 115 COVID-19 confirmed patients (mean age, 40 years), 56.5% were males and 43.5% were females. Of those vaccinated, 47.1% had received a one-dose vaccination; 52.9% had received two-dose vaccinations, and 23.6% were unvaccinated. Of those vaccinated, 72.1% had received the Pfizer BioNTech vaccine, and 16.5% had received the Oxford-AstraZeneca vaccine. The Delta variant of SARS-CoV-2 was prevalent in most (87.8%) patients. Among those infected, 28.8% reported contact with another COVID-19 case, and 19.8% reported a travel history. Most cases (68.6%) were moderate, 99.4% of patients recovered, and one patient died from COVID-19. Conclusion Most of the cases were primary infections, and the Delta variant was predominant and highly transmissible. Most COVID-19 patients were mild to moderately ill. A better understanding of the transmission and diagnosis of these variants will help in early detection and reduction of infection by application of the best preventive measures.

show abstract

SARS-CoV-2 Delta Variant Predominant at a Tertiary-Care Hospital in Saudi Arabia

Cited by 8 publications

References 2 publications

COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers

COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers

Outcome of COVID19 in Patients With Osteogenesis Imperfecta: A Retrospective Multicenter Study in Saudi Arabia

Types of Variants Among Increased Cases of COVID-19 in the Western Region of Saudi Arabia in June 2021

Contact Info

Product

Resources

About